GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>What does this GlycoFi announcement mean re GTCB's technique?<

While Aslan addresses the scientific side of the answer, I’ll address the business side. The fact that MRK paid $400M in cash for GlycoFi is perhaps the clearest evidence there is that GTCB is an undervalued stock.

GlycoFi has some promising technology that may some day pass muster with regulators and lead to the approval of a drug produced in transgenic plants. But as we have seen with GTC and Pharming, these regulatory approvals do not come easily.

GTC, with an approved drug—and consequently an approved technology platform—ought to be worth as least as much as GlycoFi based on any rational valuation analysis.